Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 28;31(7):773–790. doi: 10.1038/s41422-020-00464-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Co-IP assay with suprarenal aortas from C57BL/6 J mice. Left panel, vascular extracts were incubated with an anti-AT1 antibody or control IgG, followed by Protein A/G agarose beads. The COMP protein was examined using a western blot analysis. Right panel, vascular extracts were immunoprecipitated with an anti-COMP antibody or control IgG. The AT1 protein was then examined using a western blot analysis. Input was evaluated using aortic lysates before immunoprecipitation. n = 3; *P < 0.05 by the unpaired Student’s t-test. b Proximity ligation assay of AT1 receptor and COMP using specific antibodies on cross-sections of suprarenal aortas from 5-month-old male mice. n = 3; *P < 0.05 by the unpaired Student’s t-test. Scale bars, 50 μm. c SPR sensorgrams of the binding of an increasing amount of COMP to AT1 receptor captured on a CM5 chip. The increase in RUs from baseline was measured and used to calculate the binding kinetics, including association constant (K_a), dissociation constant (K_d) and affinity constant (K_D) for COMP binding to immobilized AT1 receptor. d Structural representation of the AT1 receptor with a TC-tag (CCPGCC) inserted at corresponding sites in ECL1, ECL2 or ECL3 as AT1-FlAsH plasmids, which were further separately co-transfected with COMP-RLuc into HEK293T cells. e Saturation BRET signal between RLuc and FlAsH in HEK293T cells co-transfected with a fixed amount of COMP-RLuc plasmid and an increasing amount of AT1-ECL-FlAsH plasmids (n = 3). f Saturation BRET signal between RLuc and FlAsH in HEK293T cells co-transfected with a fixed amount of COMP-RLuc plasmid and an increasing amount of AT1-ECL1-FlAsH or AT2-ECL1-FlAsH plasmids (n = 3). g Mammalian two-hybrid analysis of the AT1–COMP interaction. COS-7 cells were transiently transfected with various domain constructs of AT1a receptor in the pBIND vector, together with COMP fused into the pACT vector. Cells were lysed after 48 h, and the luciferase activity was determined. The data are presented as the means ± SEM of 3 independent experiments performed in triplicate. *P < 0.05 by Two-way ANOVA followed by the Bonferroni test. h Saturation BRET signal between RLuc and FlAsH in HEK293T cells co-transfected with a fixed amount of COMP-RLuc plasmid and an increasing amount of AT1-ECL1-FlAsH or a chimeric AT1-ECL1-FlAsH with the alternative N-terminus from AT2 receptor (n = 3).